Viking Therapeutics, Inc. (VKTX)
28.50
+0.77
(+2.78%)
USD |
NASDAQ |
Oct 09, 15:30
Viking Therapeutics Enterprise Value : 2.737B for Oct. 8, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 08, 2026 | 2.737B |
| October 07, 2026 | 2.832B |
| October 06, 2026 | 2.813B |
| October 05, 2026 | 2.918B |
| October 02, 2026 | 2.995B |
| October 01, 2026 | 3.062B |
| September 30, 2026 | 3.305B |
| September 29, 2026 | 3.213B |
| September 28, 2026 | 3.355B |
| September 25, 2026 | 3.651B |
| September 24, 2026 | 3.789B |
| September 23, 2026 | 4.361B |
| September 22, 2026 | 4.268B |
| September 21, 2026 | 3.015B |
| September 18, 2026 | 2.884B |
| September 17, 2026 | 2.927B |
| September 16, 2026 | 2.946B |
| September 15, 2026 | 2.996B |
| September 14, 2026 | 3.180B |
| September 11, 2026 | 3.233B |
| September 10, 2026 | 3.250B |
| September 09, 2026 | 3.317B |
| September 08, 2026 | 3.431B |
| September 04, 2026 | 3.570B |
| September 03, 2026 | 3.466B |
| Date | Value |
|---|---|
| September 02, 2026 | 3.410B |
| September 01, 2026 | 3.430B |
| August 31, 2026 | 3.326B |
| August 28, 2026 | 3.254B |
| August 27, 2026 | 3.452B |
| August 26, 2026 | 3.513B |
| August 25, 2026 | 3.488B |
| August 24, 2026 | 3.379B |
| August 21, 2026 | 3.456B |
| August 20, 2026 | 3.511B |
| August 19, 2026 | 3.700B |
| August 18, 2026 | 3.395B |
| August 17, 2026 | 3.425B |
| August 14, 2026 | 3.374B |
| August 13, 2026 | 3.345B |
| August 12, 2026 | 3.471B |
| August 11, 2026 | 3.445B |
| August 10, 2026 | 3.520B |
| August 07, 2026 | 3.499B |
| August 06, 2026 | 3.387B |
| August 05, 2026 | 3.411B |
| August 04, 2026 | 3.345B |
| August 03, 2026 | 3.306B |
| July 31, 2026 | 3.205B |
| July 30, 2026 | 3.365B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Vertex Pharmaceuticals, Inc. | 121.61B |
| Eli Lilly & Co. | 1.147T |
| Regeneron Pharmaceuticals, Inc. | 71.17B |
| Amgen, Inc. | 263.58B |
| Ironwood Pharmaceuticals, Inc. | 957.22M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -128.02M |
| Total Expenses (Quarterly) | 128.02M |
| EPS Diluted (Quarterly) | -1.101 |
| Earnings Yield | -16.36% |
| Normalized Earnings Yield | -16.36 |